Embark on the future of therapeutics with Gene Vector

Discover how we are making personalized medicine a reality!
At Gene Vector, we are at the head of innovation, committed to shaping the future of healthcare through the production of Advanced Therapy Medicinal Products (ATMPs). We specialize in the development and manufacturing of modern therapies that are poised to revolutionize the treatment of a wide range of diseases. Our mission is to bring hope, health, and healing to patients around the world through the power of ATMPs.

1. www.genevectorbcn.com BIOSPAIN 2025 Presenter: Cristina Bernadó Morales, PhD Scientific Director Barcelona, 07 th October 2025

2. HOW IT STARTED… Expanding field transforming the therapeutic landscape for many patients in multiple diseases. CAR-T (Chimeric Antigen Receptor T cells) as an example of cell-based gene therapies Lentiviral vectors: most extended system used for the ex vivo genetic modification of human cells for therapeutic purposes. CAR-T CELL THERAPIES T lymphocytes genetically modified to express Chimeric Antigen Receptors (CARs) to drive them against target cells for elimination. GENE THERAPIES www.genevectorbcn.com

3. HOW IT STARTED… CHALLENGES FOR EQUITABLE ACCESS GEOGRAPHICAL DISTRIBUTION ELEVATED COSTS Marketed products have elevated costs not sustainable for health systems. Academic initiatives allow lower costs but are limited by authorization for export . www.genevectorbcn.com

4. PROPOSED STRATEGY HOW IT STARTED… Establish Gene Vector as a Pharmaceutical laboratory holding a Manufacturing & Import Authorization (MIA) to support gene therapies to be made accessible to patients worldwide by implementing a Point-of care treatment strategy : Centralized production and commercialization of viral vectors to allow their international distribution. Network of point-of-care centers for local final CAR-T production and administration close to the patients. www.genevectorbcn.com

5. HOW IT STARTED… Founded in 2021, Gene Vector is a b iotechnology company established as a Pharmaceutical Laboratory to support the development of novel Advanced Therapeutic Medicinal Products (ATMP) to make them accessible to patients worldwide. www.genevectorbcn.com Gene Vector complies with Good Manufacturing Practices (GMP) and holds a Manufacturing and Import Authorization (MIA) for the production and export of viral vectors for gene therapies. As a CDMO (Contract Development and Manufacturing Organization) we are specialized in plasmids and lentiviral vectors and we are currently expanding activity to produce additional viral vectors for gene therapy (AAV) and cell-based Advanced Therapies (CAR-T and others).

6. CAPACITIES TEAM Unique multidisciplinary, highly qualified and experienced team committed to the highest quality and clearly client-oriented. FACILITIES We have brand new Clean Room facilities to cover current needs and potential scale up challenges, already inspected, Certified and Authorized by the Spanish Medicines Agency (AEMPS). Authorization for GMP viral vector production. CLASSIFIED AREA : Class B and D Production Rooms AUXILIARY AREAS : Grey Storage / Plasmid Production Room www.genevectorbcn.com

7. PRODUCTS & SERVICES GMP MANUFACTURING Our GMP-compliant facilities are equipped to manufacture a variety of gene therapy elements ( viral vectors and plasmids) and ATMPs. QUALITY CONTROL Quality is at the core of everything we do. Our rigorous quality control processes ensure full compliance with regulatory standards. ATMP DEVELOPMENT Each ATMP is unique . We develop customized solutions that address the specific needs of each therapy. REGULATORY SUPPORT We offer expert support in the regulatory approval process, assisting you in bringing your ATMP to the market. Qualified Person (QP) services for EU. www.genevectorbcn.com CAR-T GMP for validation, comparative studies, and as production node for Clinical Trials VIRAL VECTORS GMP Clinical and Investigational lentivirus for ATMPs PLASMIDS GMP and High-Quality plasmid DNA

8. ABOUT US SOME FIGURES 7 Different lentiviral products manufactured +45 Lentiviral batches manufactured +1.100 Lentiviral doses manufactured 6 Countries distributed Europe (Spain, Netherlands, Belgium, France, Austria) and Asia (India) +10M Participation in 4 R&D funded Projects awarded with more than 10M€ from which 3,2M€ to GVB +20 Employees. Multidisciplinary and highly qualified. 29% PhDs www.genevectorbcn.com

9. LENTIVIRAL VECTOR PLATFORM TECHNOLOGY Scaled GMP Lentiviral vector Platform Technology Small-Scale GMP Lentiviral vector production I mplementing developed advanced and scaled methods for GMP lentiviral production Current manufacturing process Standardized production and quality procedures consistent and reliable adapting to client requirements and development phase GMP LENTIVIRAL VECTOR MANUFACTURING AT DIFFERENT SCALES Gene Vector’s research activity is supported through its participation in projects awarded with competitive funding INVECTO , Joint Action ISCIII-CDTI 2022, EXP 00156560 / IDI-20230060); TCR-READY , Joint Action ISCIII-CDTI 2023, EXP 00162665 / IDI-20230956; ProCell , MICINN-AEI, CPP2022-009650 www.genevectorbcn.com >100 doses / batch Bioreactor and a multistep purification process including chromatography Larger scale; Higher Purity 20 – 30 doses / batch Quality for Early Clinical Trial phases

10. RESEARCH & DEVELOPMENT FOSTERING A CULTURE OF INNOVATION Strategically reinvest the profits to drive the development of novel pharmaceutical solutions and innovative services. Explore new therapeutic areas, expand the product portfolio and enhance our own research and development capabilities. R&D ACTIVITY IN BIOTECHNOLOGY We focus on solving challenges by developing and implementing advanced and scaled methods to achieve optimized and scalable biomanufacturing bioprocesses. COMPETITIVE FUNDING AWARDED Participation in competitive projects awarded >€10M, of which €3.2M to Gene Vector. Among, Gene Vector participates as the centralized producer and distributor of the ARI-0001 lentiviruses for the European multinational Phase 2 trial that has obtained European funding (CARTALLEU). CARTALLEU Trial 2025-2026 Gene Vector’s research activity is supported through its participation in projects awarded with competitive funding INVECTO , Joint Action ISCIII-CDTI 2022, EXP 00156560 / IDI-20230060); TCR-READY , Joint Action ISCIII-CDTI 2023, EXP 00162665 / IDI-20230956; ProCell , MICINN-AEI, CPP2022-009650 www.genevectorbcn.com

11. EVENTS & AWARDS www.genevectorbcn.com Gene Vector selected as top 5 finalists of the Merck’s EMEA Biotech Grant Program award Pitch presentation at BIO-Europe 2024 Stockholm, Sweden Our First Exhibit at the ATE London 2025 We attended BIOSPAIN 2025 (October 7-10, 2025) Gene Vector was one of the 10 Biotech Companies selected by Biocat to be at their pavilion.

12. Thank you Gene Vector Barcelona S.L. C/ de Pallars, 179-185 08005, Barcelona Tel. [phone] www.genevectorbcn.com [email protected] www.genevectorbcn.com